ARQT News and Press, Arcutis Biotherapeutics Inc. From 06/03/24

WESTLAKE VILLAGE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Goldman Sa...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-20 14:30:05 ET Summary The use of Arcutis Biotherapeutics' Zoryve for plaque psoriasis patients was expanded to include patients between the ages of 6 and 11. Sales of Zoryve grew by 675% in Q1 2024 to $21.6 million. The FDA will decide on July 7th, 2024, whether Zoryv...

2024-05-17 10:00:30 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-16 06:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-15 11:45:04 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces...

2024-05-14 19:47:10 ET Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Conference Call May 14, 2024, 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer ...

2024-05-14 16:22:07 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces pricing of $150 million public offering Arcutis licenses Japanese rig...

First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 Continued gross-to-net (GTN) improvement with blended GTN across pr...

2024-05-13 17:35:40 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces pricing of $150 million public offering Arcutis licenses Japanese rig...